NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 39 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $506,010 | +92916.5% | 609,651 | -21.6% | 0.00% | – |
Q1 2023 | $544 | -32.7% | 777,148 | -51.0% | 0.00% | – |
Q4 2022 | $808 | -99.9% | 1,587,267 | -6.4% | 0.00% | -100.0% |
Q3 2022 | $1,085,000 | -50.2% | 1,695,383 | -19.9% | 0.00% | 0.0% |
Q2 2022 | $2,180,000 | -6.2% | 2,116,143 | +71.2% | 0.00% | 0.0% |
Q1 2022 | $2,323,000 | -46.7% | 1,235,707 | +36.7% | 0.00% | -50.0% |
Q4 2021 | $4,356,000 | +114.8% | 903,660 | +222.1% | 0.00% | +100.0% |
Q3 2021 | $2,028,000 | +39.1% | 280,517 | +77.6% | 0.00% | 0.0% |
Q2 2021 | $1,458,000 | -19.1% | 157,971 | +7.9% | 0.00% | 0.0% |
Q1 2021 | $1,802,000 | -10.6% | 146,349 | +2.4% | 0.00% | 0.0% |
Q4 2020 | $2,015,000 | +152.2% | 142,898 | +114.7% | 0.00% | 0.0% |
Q3 2020 | $799,000 | -76.1% | 66,565 | -67.0% | 0.00% | -80.0% |
Q2 2020 | $3,348,000 | -60.9% | 201,671 | -73.2% | 0.01% | -73.7% |
Q1 2020 | $8,568,000 | +1359.6% | 752,941 | +1480.3% | 0.02% | +1800.0% |
Q4 2019 | $587,000 | -49.7% | 47,644 | -88.4% | 0.00% | -50.0% |
Q3 2019 | $1,166,000 | – | 409,203 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |